Brief: Urogen Completes Enrollment Of Its Phase 3 Clinical Trial For Ugn-102 In Development For Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer
19/12/2022 13:01
Dec 19 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN COMPLETES ENROLLMENT OF ITS PHASE 3 CLINICAL TRIAL
FOR
UGN-102 IN DEVELOPMENT FOR LOW-GRADE, INTERMEDIATE-RISK,
NON-MUSCLE INVASIVE BLADDER CANCER (LG-IR-NMIBC)
* UROGEN ANTICIPATES SUBMITTING A NEW DRUG APPLICATION (NDA)
FOR
UGN-102 IN 2024
Source text for Eikon: ID:nBw2Bx8qXa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors